# Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

> **NCT01893372** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Hypomethylating Agent (HMA)

## Key facts

- **NCT ID:** NCT01893372
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-01-06
- **Final completion:** 2019-01-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-02-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893372, "Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01893372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*